Healthcare Review: Illumina (NASDAQ:ILMN) Offer Looking to get Rejection, Pfizer (NYSE:PFE) Lowers Canadian Viagra Price

  on Nov 23,2012 Posted in Business News ,Featured
 
Share |
We're on   

The genetic sequencing company Illumina (NASDAQ:ILMN) announced that its peer Complete Genomics (NASDAQ:GNOM) has lessened its acquisition bid of almost $114 million, or $3.30 per share, as was declared on Friday.

In September, the Genomics had decided to be purchased for $3.15 a share by BGI-Shenzhen, but in a Wednesday filing, Illuminastated that its bid was higher and was neither reliant on financing nor conditional on government acceptance as a foreign investment.

In last trading session, Illumina, Inc. (NASDAQ:ILMN) jumped +2.32% and closed at $51.69 with the total traded volume of 1.12 million shares lower than the average volume of 1.77 million. Stock’s 52 weeks high price was $55.39 and 52 weeks low price was $25.65.

Pfizer Inc (PFE) has lowered the Canadian price of its Viagra erectile dysfunction drug following the Supreme Court of Canada opened the door to sales of generic forms of the drug, the company reported on Thursday.

We are declining original Viagra’s price to be matched with generic versions as they were dedicated to safeguarding that Viagra patients carry on having access to the genuine, made by Pfizer, and at aeconomical price, Scott Wilks from Pfizer’s Canadian subsidiary stated in a report.

Pfizer Inc. (NYSE:PFE) moved up +0.29% and closed at $24.35 with the total traded volume of 27.96 million shares in last trading session. Its fifty two week range was $18.15-$26.09. The total market capitalization remained $179.28 billion.

Recently, Bristol-Myers Squibb Company (BMY) and associate Pfizer Inc. (PFE) got some motivating news with the European Commission (EC) accepting their anti-clotting medicine Eliquis (apixaban) in the EU. The acceptance in the EU logs the first acceptance of the medicine for the NVAF indication.

Bristol Myers Squibb Co. (NYSE:BMY) added +0.81% with the closing price of $32.41. The overall volume in the last trading session was 5.58 million shares. Its fifty two week range was $30.10-$36.34. The total market capitalization remained $53.50 billion.

BMY is ahead of its 52 week low with 11.98% and its last month’s price volatility remained 1.59%. Its beta coefficient was 0.45 with a target price of $35.21. Company’s current year earnings per share grew with 20.47% while the five years EPS growth rate was +28.37%.

As of latest close, Medtronic, Inc. (NYSE:MDT) shares are up about 14.61% for 2012 and recently topped out a 52-week high of $44.79 (Oct 05, 2012). Since then, it has retreated 4.55% but stands 31.98% above 52-week low. The shares advanced above the 200-Day SMA ($40.06) and are now sitting 0.74% above 50-day SMA. The performance measured for the month was +1.79% and weekly performance appeared at +4.86%.

Dendreon Corporation (NASDAQ:DNDN)’s shares touched a high of $17.04 before closing at $4.39, an increase of $0.06. The trading volume was 5.19 million shares. Since hitting a 52-week low of $3.69 on Oct 31, 2012, the stock has managed to stay 18.97% higher from that level. The latest gain caused shares to trim their 2012 loss to -42.24%.

 

 



 

Leave a Reply